Wuhan Hvsen Biotechnology Co.,Ltd.

SZSE:300871 Stock Report

Market Cap: CN¥3.9b

Wuhan Hvsen BiotechnologyLtd Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jie Han

Chief executive officer

CN¥417.4k

Total compensation

CEO salary percentagen/a
CEO tenure1.3yrs
CEO ownershipn/a
Management average tenure3yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

Improved Revenues Required Before Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stock's 30% Jump Looks Justified

Mar 25
Improved Revenues Required Before Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stock's 30% Jump Looks Justified

Hvsen Biotechnology Co., Ltd. (SZSE:300871) Not Doing Enough For Some Investors As Its Shares Slump 25%

Jan 03
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Not Doing Enough For Some Investors As Its Shares Slump 25%

Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Nov 14
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Sep 30
Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Hvsen Biotechnology Co., Ltd. (SZSE:300871) Shares Could Be 21% Below Their Intrinsic Value Estimate

Aug 21
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Shares Could Be 21% Below Their Intrinsic Value Estimate

Take Care Before Jumping Onto Hvsen Biotechnology Co., Ltd. (SZSE:300871) Even Though It's 27% Cheaper

Jun 05
Take Care Before Jumping Onto Hvsen Biotechnology Co., Ltd. (SZSE:300871) Even Though It's 27% Cheaper

Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable

Mar 29
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable

CEO

Jie Han (40 yo)

1.3yrs
Tenure
CN¥417,400
Compensation

Mr. Jie Han is Rotating General Manager of Hvsen Biotechnology Co. Ltd. from August 27, 2024. Mr. Jie Han was Deputy General Manager of Hvsen Biotechnology Co. Ltd.until August 27, 2024.

Leadership Team

NamePositionTenureCompensationOwnership
Jie Han
Rotating General Manager1.3yrsCN¥417.40kno data
Kaijie Yang
Deputy GM & CFO9yrsCN¥435.00kno data
Zexiang Liu
Director & Assistant to the GMno dataCN¥470.00kno data
Qingfeng Wang
Board Secretary3yrsCN¥291.40kno data
Jinbin Huang
Deputy General Manager5.2yrsCN¥341.30kno data
Shuo Li
Deputy General Managerno dataCN¥390.60kno data
Hujie Yu
Deputy General Manager2.3yrsCN¥422.80kno data
Qiongbi Luo
Accounting Supervisorno datano datano data
Hongxia Li
Director of Warehousing & Logistics Data and Supervisorno datano datano data
Wenge Ding
Product & Technical Service Director and Supervisor3yrsno datano data
3.0yrs
Average Tenure
45yo
Average Age

Experienced Management: 300871's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Zexiang Liu
Director & Assistant to the GM3yrsCN¥470.00kno data
Hongxia Li
Director of Warehousing & Logistics Data and Supervisorno datano datano data
Wenge Ding
Product & Technical Service Director and Supervisor3yrsno datano data
Mingdong Ran
Independent Director1.8yrsCN¥62.20kno data
Weiyuan Zhang
Chairman9yrsCN¥667.20kno data
Jian Zhou
Chairman of the Supervisory Board & Assistant to the GM3yrsCN¥259.60kno data
Xuepeng Cai
Independent Director1.8yrsno datano data
Cuiping Zhang
Director1.8yrsno datano data
Ming Wang
Independent Directorless than a yearno datano data
2.4yrs
Average Tenure
50.5yo
Average Age

Experienced Board: 300871's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/04 06:11
End of Day Share Price 2025/12/04 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Wuhan Hvsen Biotechnology Co.,Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiarui LuGuosen Securities Co., Ltd.